Breast Cancer News
Follow
Find
57.2K views | +5 today
 
Scooped by Susan Zager
onto Breast Cancer News
Scoop.it!

50 Years in Breast Cancer: Dramatic Progress in Treatment Based On an Improved Understanding of Biology

50 Years in Breast Cancer: Dramatic Progress in Treatment Based On an Improved Understanding of Biology | Breast Cancer News | Scoop.it
Dr. Monica Morrow describes the dramatic changes that have transformed breast cancer care in the last 50 years, a period in which, “the landscape of breast cancer management across the spectrum  . . . has changed so dramatically as to be virtually unrecognizable.” Her expert editorial is an overview of the major advances in risk assessment and prevention, surgery, radiation, and adjuvant systemic therapy that have resulted in decreased mortality and morbidity among patients with breast cancer.
Susan Zager's insight:

For more information about progress in breast cancer treatment read the article and/or go to: http://am.asco.org/progress-breast-cancer-research


more...
No comment yet.
Latest News, Research, and Articles of Interest
Curated by Susan Zager
Your new post is loading...
Your new post is loading...
Scooped by Susan Zager
Scoop.it!

ASCO 2015: ASCO Announces First-Ever Clinical Trial

ASCO 2015: ASCO Announces First-Ever Clinical Trial | Breast Cancer News | Scoop.it

"ASCO announced its first-ever clinical trial, which will offer patients with advanced cancer access to molecularly targeted cancer drugs and collect “real-world” data on clinical outcomes, to help learn the best uses of these drugs outside of indications approved by the U.S. Food and Drug Administration (FDA). Plans for the Targeted Agent and Profiling Utilization Registry (TAPUR) study, including the participation of major pharmaceutical companies that will contribute free drugs, were discussed on June 1 at the 2015 ASCO Annual Meeting in Chicago.

The ASCO-sponsored prospective, nonrandomized clinical trial will collect information on the antitumor activity and toxicity of commercially available, targeted cancer drugs in a range of cancer types, including any advanced solid tumor, multiple myeloma, or non-Hodgkin lymphoma, with a genomic variation known to be a drug target.

“Oncologists often use therapies approved for a specific cancer indication to treat people with other types of advanced cancer, but we very rarely learn from that experience to benefit other patients,” said 2014–2015 ASCO President Peter Paul Yu, MD, FACP, FASCO. “TAPUR will document the real-world experience of patients who receive commercially available, targeted anticancer drugs and will describe the effectiveness and side effects of a range of targeted agents available in this study.”

Susan Zager's insight:

For more information about TAPUR, please go to: www.asco.org/TAPUR

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Faces of Breast Cancer

Faces of Breast Cancer | Breast Cancer News | Scoop.it
If you live with breast cancer, love someone with breast cancer or worry about your risk for breast cancer, you are part of a global community of women and men whose lives have been touched by the disease. Here are photos and insights from your experiences with breast cancer.
Susan Zager's insight:

Here's a great way to see firsthand personal experiences wit the disease of breast cancer. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Scientists discover how to stop breast cancer spreading to bones

Scientists discover how to stop breast cancer spreading to bones | Breast Cancer News | Scoop.it

Secondary tumours in the bones cause roughly 85 per cent of deaths from breast cancer. Now Sheffield scientists have found a drug which may stop cancer penetrating the bones.

Susan Zager's insight:

To see the study go to: http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14492.html


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Government says four cancer charities are shams

Government says four cancer charities are shams | Breast Cancer News | Scoop.it

"Wn a rare joint action with attorneys general for each of the 50 states, the Federal Trade Commission says four cancer charities run by extended members of the same family conned donors out of $187 million from 2008 through 2012 and spent almost nothing to help actual cancer patients.

Each of the charities charged were the subject of extensive reporting by CNN in 2013. And in each instance, none of the four charities would comment. We were ordered out of the building at the Cancer Fund of America in Knoxville, Tennessee, and were the object of an obscene gesture by the CEO of The Breast Cancer Society in Mesa, Arizona.
The Cancer Fund of America is run by James Reynolds Sr. His son James Reynolds Jr. is the CEO of the Breast Cancer Society. Another charity, the Children's Cancer Fund of America, is run by Rose Perkins, the ex-wife of the elder James Reynolds. He's also the CEO of the fourth charity, Cancer Support Services."
Susan Zager's insight:

To see the ratings of organizations and information check out Charity Navigator at: http://www.charitynavigator.org/


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Breast cancer and nuclear power - statistics reveal the link 'they' wanted to hide

Breast cancer and nuclear power - statistics reveal the link 'they' wanted to hide | Breast Cancer News | Scoop.it
The link between nuclear power and cancer is real, writes Chris Busby, and revealed in the UK's cancer statistics - if only you look for it. Previous approaches have focused on rare cancers over large, poorly selected populations. But look at common cancers among those most exposed to nuclear radiation, and the statistical evidence is overwhelming.
Susan Zager's insight:

This article raises many questions for the relationship of breast cancer and nuclear power. To see the  Breast Cancer Mortality in Estuary Wards near Bradwell Nuclear Power Station research study go to: http://jacobspublishers.com/images/Epidemiology/J_J_Epidemiol_Prevent_1_1_006.pdf


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New blood tests, liquid biopsies, may transform cancer care

New blood tests, liquid biopsies, may transform cancer care | Breast Cancer News | Scoop.it

"A new type of blood test is starting to transform cancer treatment, sparing some patients the surgical and needle biopsies long needed to guide their care.

The tests, called liquid biopsies, capture cancer cells or DNA that tumors shed into the blood, instead of taking tissue from the tumor itself. A lot is still unknown about the value of these tests, but many doctors think they are a big advance that could make personalized medicine possible for far more people.

They give the first noninvasive way to repeatedly sample a cancer so doctors can profile its genes, target drugs to mutations, tell quickly whether treatment is working, and adjust it as the cancer evolves.

Two years ago, these tests were rarely used except in research. Now, several are sold, more than a dozen are in development, and some doctors are using them in routine care."

Susan Zager's insight:

For more information about liquid biopsies and how it works go to: http://www.guardanthealth.com/guardant360/?gclid=Cj0KEQjwstaqBRCT38DWpZjJotIBEiQAERS6_DDO1GG72QDfjaT5SmAmN7r9MbMdKXh9M-sBe-EKrAwaAsrR8P8HAQ#


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Veterans question agency officials about contaminated water

Veterans question agency officials about contaminated water | Breast Cancer News | Scoop.it

"A panel of veterans and dependents questioned agency officials this week on behalf of victims of contaminated water at Camp Lejeune.

The Community Assistance Panel, known as CAP, held an open dialogue session Wednesday with representatives from Veterans Affairs (VA), Agency for Toxic Substances and Disease Registry (ATSDR) and Department of Defense about discrepancies in the VA claims process, current status of health studies and future actions. CAP members work directly with the Marines, sailors and their families — an estimated one million people — who have been affected by exposure, occurring approximately from 1957 to 1989.

Several of the members are victims themselves.

Mike Partain, a dependent of a Marine who served at Camp Lejeune, is one of 90 men diagnosed with breast cancer from the exposure."

Susan Zager's insight:

CAP was created by the CDC in order to represent the victims of the worst water contamination case in United States history at Camp Lejeune. For more information about the various diseases, victims and meetings by CAP as well as breast cancer exposure go to: https://lejeunecap.wordpress.com/

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Co-Sponsor S. 746 - Accelerating the End of Breast Cancer Act - Support the Mission of NBCC

Co-Sponsor S. 746 - Accelerating the End of Breast Cancer Act - Support the Mission of NBCC | Breast Cancer News | Scoop.it
An alert asking for advocates to ask their congressperson to Co-Sponsor S. 746 - Accelerating the End of Breast Cancer Act
Susan Zager's insight:

Flood Congress with emails on Lobby Day to support Accelerating the End of Breast Cancer Act. Sign this easy petition! 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Israeli Scientists Make Breakthrough in War on Cancer

Israeli Scientists Make Breakthrough in War on Cancer | Breast Cancer News | Scoop.it

Israel has made an exciting breakthrough in cancer research, offering a glimmer of hope that a cure will be found. 

The two crucial proteins, known as KPC1 and p50, were found during ongoing research on the ubiquitin system, an important and vital pathway in the life of the cell, which is responsible for the degradation of defective proteins that could damage the cell if not removed. The ubiquitin system tags these proteins and sends them for destruction in the cellular complex known as the proteasome.  The system also removes functional and healthy proteins that are no longer needed, thus regulating the processes that these proteins control.

High levels of KPC1 (which generates p50) and p50 (the product of the process), together with other processes in the cell, suppress the malignant growth and apparently protect the healthy tissue.

The research was conducted on models of human tumors grown in mice, as well as on samples of human tumors, and a strong connection was discovered between the suppression of malignancy and the level of the two proteins, clearly indicating that the increased presence of KPC1 and p50 in the tissue can protect it from cancerous tumors."

Susan Zager's insight:

To see the study go to: http://www.cell.com/cell/pdf/S0092-8674%2815%2900254-8.pdf


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Voices: Making smart decisions about breast cancer

Voices: Making smart decisions about breast cancer | Breast Cancer News | Scoop.it

"Women around the world make difficult decisions about breast cancer every day. In 2013, Angelina Jolie made the difficult decision to have a double mastectomy and to make that very personal decision public.

Of course, she did not choose to remove healthy body parts on a whim. There was scientific evidence that she had a rare genetic mutation and other characteristics that put her at very high risk of getting breast and ovarian cancer.

Angelina Jolie reveals she had double mastectomy

The possibilities open to her to minimize that risk were not at all good: vigilance ... or chemoprevention drugs; vigilance ... or surgery; and vigilance. All but the last came with their own harms.

Last week, actress Rita Wilson made headlines when she announced her breast cancer. She has a rare condition that put her at higher than average risk of getting breast cancer, pleomorphic lobular cancer in situ. A biopsy was negative, but she had a second, then a third pathology opinion that showed breast cancer. She had a double mastectomy.

Susan Zager's insight:

Fran Visco makes the important point that everyone must understand their personal risks when it comes to deciding about surgery and/or treatments are relevant to their specific cases.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

WHO Joins the Push for Greater Disclosure of Clinical Trial Data

WHO Joins the Push for Greater Disclosure of Clinical Trial Data | Breast Cancer News | Scoop.it

"In the latest push to expand access to clinical trial data, the World Health Organization has released a new position statement calling for companies to publish all research studies and suggested specific timetables for making the information available.

The move comes amid growing clamor from academics and consumer groups to press drug and device makers to release trial data. At issue is the ability for researchers to independently verify study results and, consequently, improve patient treatments that can lead to better health and lower costs.

Concerns have been heightened following various safety scandals that revealed trial data for some products was never fully published or disclosed. In recent months, regulators in the U.S. and Europe have responded by releasing new rules designed to widen access. And several drug makers, in varying degrees, have taken steps to release trial data (see here and here).

In explaining its position, the WHO notes that the failure to fully report trial data can foster misinformation, raise health care costs and distort public policy. The agency, which also published a rationale in the PLOS Medicine journal, also maintains that “it is unethical to conduct human research without publication and dissemination of the results of that research.”

Specifically, the WHO says companies should update information already provided to trial registries and submit findings for publication in peer-reviewed journals within 12 months of finishing studies. The agency also says companies should ensure there is so-called ‘open access’ publication, which refers to freely available access. Moreover, the WHO adds that results from past studies should also be disclosed."

Susan Zager's insight:

For more information go to: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001819


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Rita Wilson Has Breast Cancer, Undergoes Double Mastectomy and Reconstructive Surgery

Rita Wilson Has Breast Cancer, Undergoes Double Mastectomy and Reconstructive Surgery | Breast Cancer News | Scoop.it

"Rita Wilson is sharing some difficult and very personal news: she was recently diagnosed with breast cancer and has undergone a double mastectomy and reconstructive surgery.

In an exclusive statement to PEOPLE, the actress, 58, reveals the diagnosis and how she feels "blessed" to have the love and support of her husband, Tom Hanks, friends, family and the doctors who saved her life.

"I have taken a leave from the play Fish in the Dark to deal with a personal health issue," reveals Wilson, who will return to the Broadway play on May 5. "Last week, with my husband by my side, and with the love and support of family and friends, I underwent a bilateral mastectomy and reconstruction for breast cancer after a diagnosis of invasive lobular carcinoma. I am recovering and most importantly, expected to make a full recovery. Why? Because I caught this early, have excellent doctors and because I got a second opinion.

"I have had an underlying condition of LCIS, (lobular carcinoma in situ) which has been vigilantly monitored through yearly mammograms and breast MRIs. Recently, after two surgical breast biopsies, PLCIS (pleomorphic carcinoma in situ) was discovered. I mention this because there is much unknown about PLCIS and it is often found alongside DCIS (ductal carcinoma in situ). I was relieved when the pathology showed no cancer."

Susan Zager's insight:

Rita is very open about her experience with breast cancer and shows how important it is to get a second opinion. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Annual Conference for Women Living with Metastatic Breast Cancer

Annual Conference for Women Living with Metastatic Breast Cancer | Breast Cancer News | Scoop.it
Living Beyond Breast Cancer -- LBBC connects people with trusted breast cancer information and a community of support.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer | Breast Cancer News | Scoop.it

"Behind the headline presentations here at ASCO, you'll find one of the biggest players in immuno-oncology quietly positioning itself to vault into a leading role in the fast-emerging market, using its in-house technology to best identify the patients most likely to respond to their checkpoint inhibitor and then rapidly exploiting that edge with a full slate of combination therapies matched to their lead program. 

Genentech arrived at ASCO with a new name for MPDL3280A--it's atezolizumab now, or just "atezo" for shorthand--which is in 10 Phase III studies (an 11th is being readied) amid a blizzard of 36 clinical trials. An abstract to be posted here at ASCO points to newly identified subpopulations of lung cancer patients who may turn out to be ideally suited to atezo, which has "breakthrough" status at the FDA as regulators appear eager to approve these new drugs.

There's also an intriguing experimental treatment now in Phase I--the "anti-CEA" RG7802 program--that promises to add a brand new T cell approach to fighting cancer that is being lined up for a combo approach with atezo. Investigators are using bispecific antibody technology to direct a T cell attack directly against the CEA antigen that clusters on the surface of cancer cells. And Dan Chen, Genentech's global development team leader for immuno-oncology, says using that in combination with atezo "makes total sense."

Susan Zager's insight:

According to Chen, "The bispecific antibody RG7802 treatment is "similar to but different from CAR-T," referring to the hot new field that reengineers T cells with a chimeric antigen receptor to direct an attack against cancer cells. In this case, Genentech has designed a bispecific antibody that attaches to cancer cells as well as T cells. T cells that would normally be circulating in search of an invader like the flu are redirected to attack cancer cells. In preclinical studies, he says, it has looked like one of the most potent cancer therapies he's seen. 

In Chen's view of the next few years, the development of their checkpoint inhibitors will move past chemotherapy combinations to new approaches that involve a big step up through the use of more innovative matchups, with pipeline agents coming in to amp up impact. Roche has also paired itself with immatics biotechnologies, a German biotech that's been working on new cancer vaccines. And there's an anti-OX40 approach that stimulates the production of T cells.

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer

Palbociclib More Than Doubles PFS in Pretreated HR+/HER2- Breast Cancer | Breast Cancer News | Scoop.it
In the phase III PALOMA-3 trial, adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients with HR-positive, HER2-negative breast cancer.
Susan Zager's insight:

To see the study go to: http://meeting.ascopubs.org/cgi/content/short/33/15_suppl/LBA502?rss=1


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Researchers question genetic tests for breast cancer

Researchers question genetic tests for breast cancer | Breast Cancer News | Scoop.it
In a paper published on Wednesday in the New England Journal of Medicine, researchers have brought forward the argument that genomic test for detecting breast cancer should only be offered, if its clinical validity has been established.
more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

L'Oreal: Cosmetics With Cancer Chemicals are Not So Glamorous!

L'Oreal: Cosmetics With Cancer Chemicals are Not So Glamorous! | Breast Cancer News | Scoop.it

"There’s nothing glamorous about finding cancer-causing chemicals in our favorite mascara, eye liner or powder. Tell L’Oreal: we demand cosmetics without cancer!

The Campaign for Safe Cosmetics’ investigation of L’Oreal products revealed a shocking use of carcinogens in its eye makeup. But that’s not the half of it! We also found cancer-causing chemicals in anti-aging creams, nail polish and hair products made by L’Oreal’s most iconic brands Maybelline and Garnier.

Kids’ products aren’t free of cancer-causing chemicals either. The Campaign found DMDM hydantoin in L’Oreal Kids 2-in-1 shampoos, a chemical that releases the carcinogen formaldehyde to preserve the product."

Susan Zager's insight:

Signing this petition is easy and will only take a minute. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

A blood test for early detection of breast cancer metastasis

A blood test for early detection of breast cancer metastasis | Breast Cancer News | Scoop.it

 "Research findings from Lund University in Sweden now provide new hope for a way of detecting metastases significantly earlier than is currently possible.

 The chances of being cured of breast cancer have increased in recent decades, however if the tumour has metastasised, the disease remains essentially incurable. One reason for this could be that the metastases are detected late, after they have grown enough to cause symptoms or be seen on a radiological scan. If they could be found sooner, it might be possible to treat the new tumours. Research findings from Lund University in Sweden now provide new hope for a way of detecting metastases significantly earlier than is currently possible.

The discovery was made by a research team led by Lao Saal, M.D. Ph.D, and is based on what is known as cell-free circulating DNA – small fragments of genetic material from different cells which circulate in the blood. It is normal to have low amounts of such DNA material in the blood, but in the case of diseases such as cancer, these amounts can increase. Furthermore, in cancer patients, the circulating DNA contains the genetic mutations which are specific to the tumor.

 Lao Saal and his colleagues used previously gathered material from a breast cancer study which has been underway in Lund since 2002. The material contained samples from surgically removed tumours from patients with non-metastatic disease as well as blood samples taken from the patients at regular intervals during the years in which they were followed up.

The tumour samples contained many genetic changes, which constituted a "fingerprint" specific to each tumour. Researchers then looked in the blood samples for circulating tumour DNA (ctDNA) with the same fingerprint. Although the study is fairly small – it is based on material from only 20 women –the results are striking."

Susan Zager's insight:

To see the full research article published in Embo press go to: http://embomolmed.embopress.org/content/early/2015/05/12/emmm.201404913


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

ASCO Annual Meeting

ASCO Annual Meeting | Breast Cancer News | Scoop.it

"The annual ASCO Meeting will take place on May 29-June 2 in Chicago, Illinois at McCormick Place."

Susan Zager's insight:

Here's all the information for the annual meeting including registration for patient advocates. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Loss of TGF-beta signaling in breast cancer impairs response

Loss of TGF-beta signaling in breast cancer impairs response | Breast Cancer News | Scoop.it
Below-normal amounts of the protein TGFBR2 may be predictive of breast cancer resistance to the anti-estrogen drug tamoxifen, according to study results.Estrogen is a hormone that forces cells to grow and divide while the transforming growth factor (TGF)-beta cell signaling pathway exerts effects of growth-inhibition, according to study background. Both estrogen and TGF-beta signaling pathways
Susan Zager's insight:

To see the study go to: http://www.ncbi.nlm.nih.gov/pubmed/25833830


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Senators Dianne Feinstein and Mike Enzi Introduce Bill to Reauthorize Breast Cancer Research Stamp

Senators Dianne Feinstein and Mike Enzi Introduce Bill to Reauthorize Breast Cancer Research Stamp | Breast Cancer News | Scoop.it

"May 1, 2015 - Washington—Senators Dianne Feinstein (D-Calif.) and Mike Enzi (R-Wyo.) this week introduced a bill to renew congressional approval for the breast cancer research stamp, which has raised $80.4 million for breast cancer research since its creation in 1998. Representatives Jackie Speier (D-Calif.) and Cynthia Lummis (R-Wyo.) introduced companion legislation in the House of Representatives.


The breast cancer research stamp provides first-class postage and currently costs 60 cents. The additional 11 cents over the regular postal rate helps fund breast cancer research at the National Institutes of Health and the Medical Research Program at the Department of Defense. This bill would reauthorize the stamp through 2019. If the stamp is not reauthorized by the end of the year, it will no longer be available to the public.

“Breast cancer is the most commonly diagnosed cancer in women, claiming 40,000 lives each year,” said Senator Feinstein. “This stamp offers Americans a simple way to contribute to breast cancer research. The research funded by the stamp over the past 17 years has led to advances in screening, diagnosis and treatment—we must ensure this research continues.”

Susan Zager's insight:

For a detailed history of the breast cancer stamp go to: http://en.wikipedia.org/wiki/Breast_cancer_research_stamp#History_and_description



more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

New breast cancer gene identified

New breast cancer gene identified | Breast Cancer News | Scoop.it
A new breast cancer gene has been identified in a study led by Women's College Hospital (WCH) researcher Dr. Mohammad Akbari, who is also an assistant professor with the Dalla Lana School of Public Health at the University of Toronto. The study, which was published online today in Nature Genetics, describes ...
Susan Zager's insight:

For more information see the study at:  http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3284.html

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Blood test predicts future breast cancer risk - Futurity

Blood test predicts future breast cancer risk - Futurity | Breast Cancer News | Scoop.it

A new test that analyzes all compounds (metabolites) in a blood sample can predict with 80 percent accuracy the likelihood a woman will develop breast cancer within the next two to five years.

While the new method, called a metabolic blood profile, is not perfect, says Rasmus Bro, a professor of chemometrics at the University of Copenhagen, it appears to offer some advantages over mammography, which can detect newly developed breast cancer with a sensitivity of 75 percent.

“The method is better than mammography, which can only be used when the disease has already occurred,” says Bro, who stresses that the method has been tested and validated only for a single population (cohort) and needs to be validated more widely before it can be used practically.

Nevertheless, the method could create a paradigm shift in early diagnosis of breast cancer as well as other diseases.

“The potential is that we can detect a disease like breast cancer much earlier than today. This is important as it is easier to treat if you discover it early,” says Lars Ove Dragsted, a professor of biomedicine.

The method was developed in cooperation with the Danish Cancer Society, and the study was recently published in Metabolomics.

Holistic approach

The new approach involves analyzing all compounds in a blood sample instead of a single biomarker.

“When a huge amount of relevant measurements from many individuals is used to assess health risks—here, breast cancer—it creates very high quality information. The more measurements our analyses contain, the better the model handles complex problems,” explains Bro."

Susan Zager's insight:

This has only been studied on a small cohort but the concept should be looked at with a larger study. nload-v2.springer.com/static/pdf/829/art%253A10.1007%252Fs11306-015-0793-8.pdf?token2=exp=1429294699~acl=%2Fstatic%2Fpdf%2F829%2Fart%25253A10.1007%25252Fs11306-015-0793-8.pdf*~hmac=8d0728ba1061ba050a7cc70bf874898743170ab85d01188834e36ae5e8c76e28


more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

Study Finds Price of Cancer Drugs Varies Widely Based on Who’s Paying

Study Finds Price of Cancer Drugs Varies Widely Based on Who’s Paying | Breast Cancer News | Scoop.it

"Uninsured cancer patients are paying anywhere from 2 to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill. These findings were published by Dusetzina et al in Health Affairs.

Major Discrepancies

Researchers led by Stacie Dusetzina, PhD, Assistant Professor in the Eshelman School of Pharmacy and the Gillings School of Global Public Health, and a member of the UNC Lineberger Comprehensive Cancer Center, reviewed newly available Medicare data on what physicians charged for chemotherapy drugs delivered intravenously in 2012.

Uninsured patients who did not negotiate the billed amounts could expect to pay $6,711 for an infusion of the colorectal cancer drug oxaliplatin. However, Medicare and private health plans only pay $3,090 and $3,616 for the same drug, respectively.

Although uninsured cancer patients paid on average two times more than Medicare paid for expensive chemotherapy drugs, very high payment differences were seen for drugs that were quite inexpensive on Medicare. For example, carboplatin was estimated at $26 for one infusion with Medicare, but the estimate for uninsured patients was $1,124."

Susan Zager's insight:

This is a complex issue to solve but the problems with the cost of cancer medications and the disparities between pricing clearly are disturbing. 

more...
No comment yet.
Scooped by Susan Zager
Scoop.it!

MBCN Supports Metastatic Breast Cancer Researchers With Total Of $100,000 In Awards

MBCN Supports Metastatic Breast Cancer Researchers With Total Of $100,000 In Awards | Breast Cancer News | Scoop.it

"PRLog - April 10, 2015 - NEW YORK -- The Metastatic Breast Cancer Network (MBCN) announced the 2015 recipients of its Metastatic Breast Cancer Research Leadership Awards: Dr. Andrew Ewald, associate professor in the Departments of Cell Biology and Oncology at the Johns Hopkins University School of Medicine and Dr. Matthew Ellis, the director of the Lester and Sue Smith Breast Center at Baylor College of Medicine.

The Metastatic Breast Cancer Network (MBCN), an all-volunteer, patient-led organization, has long advocated for more focused metastatic breast cancer research that improves outcomes in the clinic for patients with metastatic breast cancer, an incurable disease that ends the lives of 108 people every day of the year.

“In 2014, MBCN made a commitment that all memorial contributions made to MBCN would go to funding metastatic research,” said Shirley Mertz, President. “We are pleased to present leadership awards of $50,000 each to two individuals whose work contributes significantly to understanding basic knowledge about the process of metastasis and to improving how patients are treated.”

Mertz, living with metastatic breast cancer since 2003, noted that although metastatic breast cancer is responsible for virtually every breast cancer death, it receives only a tiny percentage of the billons dedicated to breast cancer research. “MBCN is a founding member of The Metastatic Breast Cancer Alliance,” Mertz said. “The Alliance’s Metastatic Breast Cancer Landscape Analysis released in October 2014 found that metastatic focused research made up only 7% of the $15 billion invested in breast cancer research from 2000 to 2013 by the major governmental and nonprofit funders from North America and the United Kingdom. Breast cancer remains the second leading cause of cancer death for women in the US, and it is the leading cause of cancer death for women globally. We know research "

Susan Zager's insight:

There's tons of great information in this article about the importance of metastatic breast cancer research. For more information about the MBCN go to: http://mbcn.org/

more...
No comment yet.